Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features

Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1

(2017) Wei Wang et al.   Experimental and Therapeutic Medicine

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy

(2017) Azael Freites-Martinez et al.   JAMA Dermatology

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma

(2017) Kristian M. Hargadon   Frontiers in Immunology

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

(2016) George Jour et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma

(2016) Mark C. Mochel et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

(2016) Jonathan L. Curry et al.   JOURNAL OF CUTANEOUS PATHOLOGY

PD-1 inhibitors induced bullous lichen planus-like reactions

(2016) Deepal V. Wakade et al.   MELANOMA RESEARCH

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cutaneous adverse effects of targeted therapies

(2015) James B. Macdonald et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab

(2015) Giuliana Carlos et al.   MELANOMA RESEARCH

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions

(2013) Jonathan L. Curry et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications

(2010) William K.K. Wu et al.   INTERNATIONAL JOURNAL OF CANCER